Watching Infinity Pharmaceuticals Inc. (INFI) For Insider Activity

Business man trader investor analyst using mobile phone app analytics for cryptocurrency financial stock market analysis analyze graph trading data index investment growth chart on smartphone screen.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) traded with an addition of $0.02 to close at $0.51 on Thursday, an upside of 4.01 percent. An average of 803,546 shares of common stock have been traded in the last five days. There was a fall of -$0.0125 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 849,297 shares traded, while the 50-day average volume stands at 678,089.

INFI stock has decreased by -8.06% in the last month. The company shares reached their 1-month lowest point of $0.4441 on 12/07/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.44 and a high of $2.44 in 52 weeks. It has reached a new high 1 time so far this year and lost -78.04% or -$1.7425 in price. In spite of this, the price is down -78.92% from the 52-week high.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

Infinity Pharmaceuticals Inc. (INFI) stock’s beta is 1.24. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 16.99.

Financial Health

The quick ratio of Infinity Pharmaceuticals Inc. for the three months ended September 29 was 3.50, and the current ratio was 3.50, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $46.94 million compared to revenue of $1.86 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Infinity Pharmaceuticals Inc.’s return on assets was -69.10%.

Earnings Surprise

In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$10.72 million in the quarter, while revenues of -$11.99 million were grew 0.09%. The analyst consensus anticipated Infinity Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.06 per share, but it turned out to be -$0.12, a -100.00% surprise. For the quarter, EBITDA amounted to -$10.77 million. Shareholders own equity worth $89.35 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Infinity Pharmaceuticals Inc. (INFI) price momentum. RSI 9-day as of the close on 28 December was 44.74%, suggesting the stock is Neutral, with historical volatility in this time frame at 76.61%.

As of today, INFI’s price is $0.5114 -2.40% or -$0.0125 from its 5-day moving average. INFI is currently trading -7.51% lower than its 20-day SMA and -37.29% lower than its 100-day SMA. However, the stock’s current price level is -57.35% below the SMA50 and -42.33% below the SMA200.

The stochastic %K and %D were 43.48% and 54.67%, respectively, and the average true range (ATR) was 0.0510. With the 14-day stochastic at 49.34% and the average true range at 0.0578, the RSI (14) stands at 39.53%. The stock has reached -0.0077 on the 9-day MACD Oscillator while the 14-day reading was at -0.0011.

Analyst Ratings

H.C. Wainwright launched coverage on Infinity Pharmaceuticals Inc. (NASDAQ: INFI) in its analyst report released on October 18, 2021. The firm assigned the stock a Buy rating. The consensus rating for Infinity Pharmaceuticals Inc. (INFI) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell INFI, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.


Please enter your comment!
Please enter your name here